权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Texas Medical Center Regional Coordinating Center for Heart Failure

德克萨斯医疗中心心力衰竭区域协调中心

基本信息

批准号：
7653701
负责人：
Anita Deswal
金额：
$ 36.16万
依托单位：
BAYLOR COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-09-30 至 2011-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7653701
关键词：
Adult Advocate Age Autologous Basic Science Biological Markers Biological Neural Networks Bone Marrow C-reactive protein CA-125 Antigen Cardiac Cells Characteristics Childhood Chronic Clinical Clinical Research Clinical Trials Collaborations Collagen Communities Complex Conduct Clinical Trials Dental Schools Device Removal Dobutamine Stress Echocardiography Elderly Eligibility Determination Endothelial Cells Endothelin-1 Enrollment Ensure Experimental Animal Model Forensic Medicine Gender Glomerular Filtration Rate Goals Heart Transplantation Heart failure Hospitals Housing Image Inflammation Injection of therapeutic agent Institution Judgment Left Ventricular Remodeling Medical center Medicine Mesenchymal Minority Mononuclear Muscle Cells Myocardial Myocardial Ischemia N-terminal Necrosis Nursing Schools Patients Peptides Pharmacy facility Phase Phenotype Public Health Schools Race Recovery Recruitment Activity Regional Blood Flow Research Research Personnel Safety Schools Science Sensitivity and Specificity Series Site Stem cells Stress Systolic heart failure Teaching Hospitals Testing Texas Therapeutic Time Transplant Recipients Troponin T Tumor Markers United States National Institutes of Health VWF gene Ventricular Visit Weaning Woman Work abstracting acute coronary syndrome base biological systems cell type college experience follow-up functional status hemodynamics hospice environment improved medical schools medical specialties patient population post gamma-globulins pro-brain natriuretic peptide (1-76)prospective racial and ethnic stem cell therapy tool von Willebrand Factor

项目摘要

DESCRIPTION (provided by applicant): The Texas Medical Center Regional Coordinating Center for Heart Failure The proposed Texas Medical Center (TMC) Regional Coordinating Center (RCC) will be comprised of nine separate sites that are housed on the campus of the Texas Medical Center (www.tmc.edu), one of the largest incorporated medical centers in the world, with 42 not-for-profit institutions including 13 hospitals, two medical schools, two graduate schools of biomedical sciences, a dental school, four nursing schools, a school of public health, a college of pharmacy, a hospice facility, a geriatric center, a psychiatric center, and a forensic medical center, all located on the same campus. There are over 5,000,000 patient visits to the TMC, annually, which makes the TMC an ideal site to conduct clinical trials. Moreover, the racial and ethnic diversity within the TMC lends itself well to conducting clinical trials. The scientific and administrative base of this proposed RCC will be at Baylor College of Medicine. The nine sites in the TMC RCC are in close proximity to one another (see Figure 1), and most are attached by skywalks and tunnels that facilitate the interaction and collaboration between the sites. The patient characteristics, experience in clinical research in heart failure and enrollment capacity for heart failure clinical trials at each of the participating institutions is outstanding. Finally, the proposed TMC RCC has a number of unique features that are ideally suited for the NIH heart failure research network, including close proximity of all participating Institutions to one another such that a single research coordinator can recruit from all sites in the TMC network, sufficient racial diversity of the patient population to ensure adequate recruitment of minorities and women, a mixture of community and teaching hospitals, pediatric and adult hospitals, and specialty hospitals (e.g. MD Anderson), each of which has a very high patient volume for adult and pediatric heart failure. Finally the TMC RCC will be overseen by Dr. Douglas Mann, who has experience with phase I - IV clinical trials, and who has close working relationship with of the investigators in the proposed TMC RCC by virtue of his 14 year tenure in the Texas Medical Center. (End of Abstract)

描述（由申请人提供）：